Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02418806
Other study ID # cuiDem/FBB-0113
Secondary ID
Status Completed
Phase N/A
First received February 6, 2015
Last updated January 19, 2016
Start date January 2014
Est. completion date September 2015

Study information

Verified date January 2016
Source Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Contact n/a
Is FDA regulated No
Health authority Spain: Ethics Committee
Study type Interventional

Clinical Trial Summary

An experimental study designed to test the effectiveness of a psychological intervention based on group therapy for the caregivers of Alzheimer's disease patients. The intervention consists of 16 sessions of a cognitive-behavioral psychological group therapy. This study aims to demonstrate that Alzheimer's patients' caregivers can decrease the feelings of burden after been involved in a group therapy.


Recruitment information / eligibility

Status Completed
Enrollment 231
Est. completion date September 2015
Est. primary completion date July 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Main caregiver of an Alzheimer Disease Patient.

- Alzheimer Disease Patient with mild/severe cognitive impairment.

- High compliance to therapy sessions.

- Sign informed consent.

Exclusion Criteria:

- Low commitment to develop all study phases.

- Caregiver activity remunerated.

- Caregiver with psychiatric disorders that can affect the development of the sessions.

- Caregivers who have received psychological care during last year.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Psychotherapy groups

Self-help groups


Locations

Country Name City State
Spain AFA Barcelona Barcelona
Spain Centro de día Vitalia Barcelona
Spain AFA Burgos Burgos
Spain AFA Castellón Castellón
Spain AGUAFA Guadasuar
Spain AFA Lleida Lleida
Spain Centro de envejecimiento saludable Málaga
Spain Fundació Ana Ribot Pallejà
Spain AVAN Sabadell
Spain AFATE Tenerife
Spain AFA Terres de l'Ebre Tortosa

Sponsors (1)

Lead Sponsor Collaborator
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of group therapy in caregiver burden measured by Zarit Burden Interview. 16 months No
Secondary Change in caregiver burden from baseline compared to the control and active arms measured by Zarit Burden Interview. 4 months and 16 months No
Secondary Change in anxiety and depression from baseline compared to the control and active arms measured by Goldberg Scale. 4 months and 16 months No
Secondary Descriptive analysis of the caregivers' characteristics (sociodemographics, relation wih the AD patient). Baseline (0 months) No
Secondary Descriptive analysis of the caregiver's cognition using DEM-DETECT Module 1. 4 months No
Secondary Preliminary cost-effectiveness analysis related resources needed to caregivers and Alzheimer patients. 4 months - 16 months No
Secondary Change in quality of life from baseline compared to the control and active arms measured by Casp-19 and SF-36 questionnaires. 4 months - 16 months No
Secondary Change in resilience from baseline compared to the control and active arms measured by Connor-Davidson Resilience Scale. 4 months - 16 months No
Secondary Change in functional social support from baseline compared to the control and active arms using Duke-UNC questionnaire. 4 months - 16 months No
See also
  Status Clinical Trial Phase
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Withdrawn NCT03316898 - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease Phase 1
Withdrawn NCT02860065 - CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase 2
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Recruiting NCT05607615 - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease Phase 2
Terminated NCT03307993 - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease Phase 1
Recruiting NCT02912936 - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease N/A
Active, not recruiting NCT02899091 - Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease Phase 1/Phase 2
Completed NCT02907567 - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Not yet recruiting NCT02868905 - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women N/A
Completed NCT02580305 - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study Phase 2
Completed NCT02516046 - 18F-AV-1451 Autopsy Study Phase 3
Terminated NCT02521558 - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease N/A
Recruiting NCT02247180 - Cognitive Rehabilitation in Alzheimer`s Disease N/A
Terminated NCT02220738 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors Phase 1
Completed NCT02260167 - Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol N/A
Completed NCT02256306 - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study N/A
Completed NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Completed NCT01826110 - PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers Phase 1